- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update - April 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Dapagliflozin (Forxiga®) has been accepted for use in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.